激酶抑制剂：成功背后的现实
Kinase Inhibitors: The Reality Behind the Success.
作者信息
Jeon Jae Yoon, Sparreboom Alex, Baker Sharyn D
机构信息
Division of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy and Comprehensive Cancer Center, Ohio State University, Columbus, Ohio, USA.
出版信息
Clin Pharmacol Ther. 2017 Nov;102(5):726-730. doi: 10.1002/cpt.815.
Abstract
Tremendous progress has been made by utilizing kinase inhibitors in oncology, and these agents continue to pave the way into other areas of medicine. There are, however, many challenges to the application of kinase inhibitors due to inherent shortcomings of the drugs and lack of comprehensive understanding of tumor and disease biology. The future fate of kinase inhibitors, however, is bright, as evidenced from ongoing efforts to increase their efficacy while remediating their weaknesses in order to provide the best quality of care to patients.
摘要
在肿瘤学领域，激酶抑制剂的应用已取得了巨大进展，并且这些药物继续为进入医学的其他领域铺平道路。然而，由于药物固有的缺点以及对肿瘤和疾病生物学缺乏全面了解，激酶抑制剂的应用面临许多挑战。然而，激酶抑制剂的未来前景光明，目前正在努力提高其疗效并弥补其弱点，以便为患者提供最佳的医疗服务，这一点就证明了这一点。
相似文献
1
Kinase Inhibitors: The Reality Behind the Success.激酶抑制剂：成功背后的现实
Clin Pharmacol Ther. 2017 Nov;102(5):726-730. doi: 10.1002/cpt.815.
2
Kinase drug discovery 20 years after imatinib: progress and future directions.伊马替尼发现 20 年后的激酶药物研发：进展与未来方向
Nat Rev Drug Discov. 2021 Jul;20(7):551-569. doi: 10.1038/s41573-021-00195-4. Epub 2021 May 17.
3
Delayed resistance to imatinib after 16 years of therapy in a patient with chronic myeloid leukaemia.一名慢性髓性白血病患者在接受16年治疗后对伊马替尼产生延迟耐药。
Br J Haematol. 2020 Jul;190(1):e51-e53. doi: 10.1111/bjh.16723. Epub 2020 May 13.
4
Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.甲磺酸伊马替尼用于慢性髓性白血病：一线治疗及长期疗效
Expert Rev Anticancer Ther. 2016;16(3):273-8. doi: 10.1586/14737140.2016.1151356.
5
Protein kinase inhibitors.蛋白激酶抑制剂
Folia Biol (Praha). 2006;52(4):137-48.
6
Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology.个体化癌症治疗与选择性激酶抑制剂：医学肿瘤学的新兴范例。
J Clin Oncol. 2009 Nov 20;27(33):5650-9. doi: 10.1200/JCO.2009.22.9054. Epub 2009 Oct 26.
7
Next questions for the medical treatment of gastrointestinal stromal tumor.胃肠道间质瘤的治疗下一步该怎么做？
Curr Opin Oncol. 2022 Jul 1;34(4):348-353. doi: 10.1097/CCO.0000000000000845. Epub 2022 Jun 22.
8
The effectiveness of interferon-α combined with imatinib in patient with chronic myeloid leukemia harboring T315I BCR-ABL1 mutation.α干扰素联合伊马替尼治疗携带T315I BCR-ABL1突变的慢性髓性白血病患者的疗效
Leuk Lymphoma. 2018 Dec;59(12):3018-3019. doi: 10.1080/10428194.2018.1443329. Epub 2018 Apr 4.
9
Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis.高剂量伊马替尼与第二代酪氨酸激酶抑制剂一线治疗慢性期慢性髓性白血病患者的倾向评分分析
Haematologica. 2016 Aug;101(8):e324-7. doi: 10.3324/haematol.2015.139089. Epub 2016 May 12.
10
New Imatinib Derivatives with Antiproliferative Activity against A549 and K562 Cancer Cells.新型伊马替尼衍生物对 A549 和 K562 癌细胞的抗增殖活性。
Molecules. 2022 Jan 24;27(3):750. doi: 10.3390/molecules27030750.
引用本文的文献
1
New onset diabetes manifesting as diabetic ketoacidosis in a patient with chronic myelogenous leukemia treated with imatinib.在接受伊马替尼治疗的慢性粒细胞白血病患者中出现以糖尿病酮症酸中毒为表现的新发糖尿病。
Arch Endocrinol Metab. 2025 Apr 8;69(2):e240432. doi: 10.20945/2359-4292-2024-0432.
2
Non-kinase off-target inhibitory activities of clinically-relevant kinase inhibitors.临床相关激酶抑制剂的非激酶非靶标抑制活性。
Eur J Med Chem. 2024 Sep 5;275:116540. doi: 10.1016/j.ejmech.2024.116540. Epub 2024 May 31.
3
Role of c-Src in Carcinogenesis and Drug Resistance.c-Src在致癌作用和耐药性中的作用。
Cancers (Basel). 2023 Dec 20;16(1):32. doi: 10.3390/cancers16010032.
4
May EPH/Ephrin Targeting Revolutionize Lung Cancer Treatment?EPH/Ephrin 靶向治疗会给肺癌治疗带来变革吗？
Int J Mol Sci. 2022 Dec 21;24(1):93. doi: 10.3390/ijms24010093.
5
The Genetics of Parkinson's Disease and Implications for Clinical Practice.帕金森病的遗传学及其对临床实践的影响。
Genes (Basel). 2021 Jun 30;12(7):1006. doi: 10.3390/genes12071006.
6
Kinome inhibition reveals a role for polo-like kinase 1 in targeting post-transcriptional control in cancer.激酶组抑制揭示了 polo 样激酶 1 在靶向癌症转录后调控中的作用。
Mol Oncol. 2021 Aug;15(8):2120-2139. doi: 10.1002/1878-0261.12897. Epub 2021 Feb 1.
7
Role of transporters in toxicity induced by anticancer drugs.转运蛋白在抗癌药物诱导的毒性中的作用。
Expert Opin Drug Metab Toxicol. 2020 Jun;16(6):493-506. doi: 10.1080/17425255.2020.1755253. Epub 2020 Apr 26.
本文引用的文献
1
Application of 3D Mass Spectrometry Imaging to TKIs.三维质谱成像技术在 TKI 中的应用。
Clin Pharmacol Ther. 2017 Nov;102(5):748-751. doi: 10.1002/cpt.786.
2
Tyrosine Kinase Inhibitors and Male Reproductive Health.酪氨酸激酶抑制剂与男性生殖健康。
Clin Pharmacol Ther. 2017 Nov;102(5):754-756. doi: 10.1002/cpt.813. Epub 2017 Sep 25.
3
Application of Liquid Biopsies in Cancer Targeted Therapy.液体活检在癌症靶向治疗中的应用。
Clin Pharmacol Ther. 2017 Nov;102(5):745-747. doi: 10.1002/cpt.764. Epub 2017 Jul 29.
4
Health policy: Me-too drugs with limited benefits - the tale of regorafenib for HCC.卫生政策：疗效有限的仿制药——瑞戈非尼用于肝细胞癌的故事
Nat Rev Clin Oncol. 2017 Nov;14(11):653-654. doi: 10.1038/nrclinonc.2017.100. Epub 2017 Jul 18.
5
Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology.肿瘤学中激酶抑制剂治疗药物监测的实用建议
Clin Pharmacol Ther. 2017 Nov;102(5):765-776. doi: 10.1002/cpt.787. Epub 2017 Sep 7.
6
Small-molecule kinase inhibitors: an analysis of FDA-approved drugs.小分子激酶抑制剂：FDA 批准药物分析。
Drug Discov Today. 2016 Jan;21(1):5-10. doi: 10.1016/j.drudis.2015.07.008. Epub 2015 Jul 23.
7
FDA-approved small-molecule kinase inhibitors.美国食品和药物管理局批准的小分子激酶抑制剂。
Trends Pharmacol Sci. 2015 Jul;36(7):422-39. doi: 10.1016/j.tips.2015.04.005. Epub 2015 May 12.
8
Targeting cancer with kinase inhibitors.用激酶抑制剂靶向治疗癌症。
J Clin Invest. 2015 May;125(5):1780-9. doi: 10.1172/JCI76094. Epub 2015 May 1.
9
Integrating clinical pharmacology concepts in individualized therapy with tyrosine kinase inhibitors.将临床药理学概念整合到酪氨酸激酶抑制剂的个体化治疗中。
Clin Pharmacol Ther. 2013 Mar;93(3):215-9. doi: 10.1038/clpt.2012.247.
10
Targeting cancer with small molecule kinase inhibitors.用小分子激酶抑制剂靶向治疗癌症。
Nat Rev Cancer. 2009 Jan;9(1):28-39. doi: 10.1038/nrc2559.
Zotero 插件